Increasing rates of <i>erm</i>(B) and <i>erm</i>(N) in human <i>Campylobacter coli</i> and <i>Campylobacter jejuni</i> erythromycin-resistant isolates between 2018 and 2023 in France.

ABSTRACT: Macrolides are the first-line compounds used for the treatment of campylobacteriosis. Macrolide resistance remains low in France, with mutations in 23S rDNA being the main associated resistance mechanism. However, two erythromycin methyltransferases have also been identified: erm(B), which is mainly described in animal reservoirs, and erm(N), which is strictly described in humans. In France, between 2018 and 2023, erythromycin-resistant Campylobacter species strains were systematically sequenced and analyzed via an in-house bioinformatics pipeline, leading to the identification of the resistomes, MLST and cgMLST, as well as the characterization of the source of contamination. In this study, the genomes of 280 erythromycin-resistant strains were sequenced

SUBMITTER: Jehanne Q 

PROVIDER: S-EPMC11823653 | biostudies-literature | 2025 Feb

REPOSITORIES: biostudies-literature